Abstract
•Aneurysm rebleeding is a significant risk for patients presenting with aSAH.•Rebleeding is associated with the TT genotype of the EDN1 G/T SNP.•Patients suffering from rebleeding experience poor functional outcomes.
Aneurysm rebleeding following presentation with aneurysmal subarachnoid hemorrhage (aSAH) is associated with high mortality and poor functional outcome. While a substantial genetic contribution to aneurysm formation and rupture is known, the genetic influence on the risk of rebleeding is poorly understood.
To evaluate the role of common endothelin polymorphisms in aneurysm rebleeding.
Blood sample from all patients enrolled in the CARAS (Cerebral Aneurysm Renin Angiotensin System) study were used for genetic evaluation. The CARAS study prospectively enrolled aSAH patients at two academic institutions in the United States from 2012 to 2015. Common endothelin SNPs were detected using 5′exonnuclease (Taqman) genotyping assays. Analysis of associations between endothelin single nucleotide polymorphisms (SNP) and aneurysm rebleeding was performed.
One hundred and forty-nine aSAH patients were included. Acute spontaneous aneurysm rebleeding occurred in 5 (3.4%) patients. Multivariable analysis identified the TT genotype for EDN1 G/T SNP (rs2070699; OR 97.4, 95% CI 3.825–2479.984, p=0.006) as an independent risk factor for aneurysm rebleeding. Aneurysm rebleeding was associated with an unfavorable functional outcome (mRS 3–6) at last follow up in all 5 patients.
Aneurysm rebleeding following presentation with aSAH was independently associated with the TT genotype of the EDN1 G/T SNP. All patients with acute spontaneous aneurysm rebleeding suffered a poor functional outcome at last follow up.
